• Earlier in January, Zeta Global announced a collaboration with OpenAI to integrate OpenAI models into its Athena AI agent, expanding beta access to Athena’s conversational analytics and goal-driven marketing optimization tools.
• The move highlights how AI-powered agents are increasingly being embedded directly into enterprise marketing workflows, potentially reshaping how brands analyze data and adjust campaigns in real time.
• Next, we’ll explore how this deeper OpenAI integration within Athena could influence Zeta Global’s broader investment narrative and competitive positioning.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Zeta Global Holdings' Investment Narrative?

To own Zeta Global, you really have to believe in its ability to turn a growing, data-rich marketing platform into a sustainably profitable software business, while competing head to head with larger cloud and ad-tech players. The OpenAI collaboration and deeper Athena integration feed directly into that thesis by sharpening Zeta’s AI story and potentially reinforcing near term catalysts around adoption of its platform, especially as management has already raised revenue guidance and is signaling confidence with ongoing buybacks. At the same time, the stock’s recent strength and Morgan Stanley’s higher price target suggest the market may already be assigning some value to this AI angle, so the immediate financial impact may be modest until Athena-driven products scale. Key risks remain around execution, profitability timing, and whether higher spend on AI and leadership compensation deliver clear returns.

However, investors should also weigh how rising costs and rich executive pay could pressure that thesis. Zeta Global Holdings' shares have been on the rise but are still potentially undervalued by 17%. Find out what it's worth.

Exploring Other Perspectives

Across 29 fair value estimates from the Simply Wall St Community, views on Zeta Global span roughly US$14 to just over US$41 per share. That spread sits against an investment case now increasingly tied to Athena’s OpenAI integration, where execution risk and timing of profitability could meaningfully influence which side of that range proves closer to reality, so it is worth comparing several of these viewpoints before deciding what you think the stock is worth.

Explore 29 other fair value estimates on Zeta Global Holdings - why the stock might be worth as much as 90% more than the current price!

Build Your Own Zeta Global Holdings Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Zeta Global Holdings research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Zeta Global Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zeta Global Holdings' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 109 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.